Nurulain Zaveri is the Founder, President and Chief Scientific Officer of Astraea Therapeutics, a preclinical discovery company she founded in 2009, whose mission is medication development for under-served diseases of the central nervous system (such as opioid and substance abuse and addiction, chronic pain and Parkinson’s disease). A PhD medicinal chemist by training, Dr. Zaveri is a recognized expert in the field of G-protein coupled receptor-targeted- and ion channel-targeted drug discovery for CNS medications. Pioneering discoveries from her laboratory have contributed to the understanding of the pharmacology of drug addiction and pain, and are being advanced into medication development.
Before her entrepreneurial venture at Astraea Therapeutics, Dr. Zaveri was Principal Investigator and Director of the Drug Discovery Program at the Stanford Research Institute International in Menlo Park, CA, for 16 years. Dr. Zaveri has been the Chair of the Drug Discovery and Development (DDD) Section of the American Association of Pharmaceutical Scientists (AAPS). was awarded the AAPS Fellow status to recognize the significant impact of her research to the Pharmaceutical Sciences and medication development. Dr. Zaveri also serves on several NIH grant review committees. Dr. Zaveri is the lead inventor on over 12 patents and has authored over 60 research publications and 9 reviews/book chapters in fields of her research. Dr. Zaveri is a strong proponent for issues related to Career Development for Women in the Pharmaceutical Sciences and has organized and given talks on this topic at the AAPS Annual meetings. She has also been a long-time member of ACS and the MEDI Section.